Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study

Table 3 Clinical outcomes between high-intensity and low-moderate-intensity statin in three different glycemic statuses at 2 years

Outcomes	High-intensity (n = 806)	Low-moderate-intensity (n = 1815)	Log-rank	Unadjusted		Adjusted^a
Outcomes	High-intensity (n = 806)	Low-moderate-intensity (n = 1815)	Log-rank	HR (95% CI)	p value	HR (95% CI)	p value
Normoglycemia	Group A1	Group B1
MACE	23 (3.4)	104 (6.4)	0.004	1.924 (1.225–3.022)	0.005	1.903 (1.203–3.010)	0.006
All-cause death	8 (1.2)	28 (1.7)	0.311	1.497 (0.682–3.286)	0.314	1.342 (0.604–2.982)	0.471
Cardiac death	5 (0.6)	20 (1.1)	0.265	1.733 (0.650–4.619)	0.271	1.628 (0.602–4.402)	0.336
Re-MI	9 (1.4)	27 (1.7)	0.555	1.254 (0.590–2.668)	0.556	1.238 (0.570–2.690)	0.589
Any revascularization	8 (1.1)	60 (3.9)	0.001	3.146 (1.504–6.579)	0.002	3.248 (1.539–6.854)	0.002

Outcomes	High-intensity (n = 935)	Low-moderate-intensity (n = 2145)	Log-rank	Unadjusted		Adjusted^a
Outcomes	High-intensity (n = 935)	Low-moderate-intensity (n = 2145)	Log-rank	HR (95% CI)	p value	HR (95% CI)	p value
Prediabetes	Group A2	Group B2
MACE	61 (7.3)	139 (6.9)	0.656	1.071 (0.792–1.447)	0.656	1.112 (0.818–1.510)	0.499
All-cause death	21 (2.5)	48 (2.4)	0.846	1.052 (0.630–1.757)	0.846	1.103 (0.653–1.862)	0.715
Cardiac death	15 (1.7)	34 (1.7)	0.885	1.046 (0.569–1.920)	0.886	1.014 (0.542–1.897)	0.966
Re-MI	16 (1.9)	35 (1.7)	0.769	1.092 (0.605–1.974)	0.769	1.166 (0.639–2.130)	0.617
Any revascularization	28 (3.5)	60 (3.1)	0.520	1.158 (0.740–1.814)	0.521	1.152 (0.730–1.819)	0.543

Outcomes	High-intensity (n = 1243)	Low-moderate-intensity (n = 2949)	Log-rank	Unadjusted		Adjusted^a
Outcomes	High-intensity (n = 1243)	Low-moderate-intensity (n = 2949)	Log-rank	HR (95% CI)	p value	HR (95% CI)	p value
T2DM	Group A3	Group B3
MACE	96 (9.0)	254 (9.2)	0.654	1.055 (0.834–1.335)	0.654	1.010 (0.796–1.282)	0.934
All-cause death	41 (3.8)	99 (3.6)	0.876	1.029 (0.715–1.482)	0.876	1.139 (0.787–1.650)	0.491
Cardiac death	28 (2.6)	63 (2.2)	0.690	1.095 (0.701–1.709)	0.690	1.238 (0.788–1.945)	0.354
Re-MI	29 (3.0)	69 (2.6)	0.748	1.074 (0.696–1.657)	0.748	1.108 (0.713–1.720)	0.649
Any revascularization	42 (4.0)	102 (3.8)	0.843	1.037 (0.724–1.486)	0.843	1.059 (0.736–1.526)	0.756

Outcomes	High-intensity (n = 2984)	Low-moderate-intensity (n = 6909)	Log-rank	Unadjusted		Adjusted^a
Outcomes	High-intensity (n = 2984)	Low-moderate-intensity (n = 6909)	Log-rank	HR (95% CI)	p value	HR (95% CI)	p value
Total	Group A1 + A2 + A3	Group B1 + B2 + B3
MACE	180 (7.0)	497 (7.8)	0.164	1.129 (0.952–1.339)	0.164	1.070 (0.900–1.273)	0.444
All-cause death	70 (2.7)	175 (2.7)	0.824	1.032 (0.782–1.362)	0.825	1.083 (0.816–1.436)	0.581
Cardiac death	48 (1.8)	117 (1.8)	0.920	1.017 (0.727–1.424)	0.920	1.099 (0.781–1.546)	0.590
Re-MI	54 (2.2)	131 (2.1)	0.922	1.016 (0.740–1.395)	0.922	1.066 (0.771–1.473)	0.700
Any revascularization	78 (3.1)	222 (3.6)	0.285	1.151 (0.889–1.490)	0.286	1.131 (0.870–1.470)	0.358

HR: Hazard ratio; CI: confidence interval; T2DM: type 2 diabetes mellitus; MACE: major adverse cardiac events; Re-MI: recurrent myocardial infarction; LVEF: left ventricular ejection fraction; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; NT-ProBNP: N-terminal pro-brain natriuretic peptide; LDL: low-density lipoprotein; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; IVUS: intravascular ultrasound
^aAdjusted by age, male, LVEF, BMI, SBP, DBP, cardiogenic shock, hypertension, current smoker, NT-ProBNP, total cholesterol, triglyceride, LDL-cholesterol, ticagrelor, ACEI, ARB, atorvastatin, rosuvastatin, simvastatin, IVUS, and stent diameter

ISSN: 1471-2261